Inhibrx Biosciences, Inc. (INBX)
The price, the headline numbers and the latest news, in one place.
Inhibrx Biosciences, Inc. (INBX) Stock Price, Analysis & Data
| Bid | 90.34 |
| Market Cap | 1.64B |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -138M |
| 3.67 | |
| -8.79 | |
| n/a | |
| -12.72 | |
| P/B (ttm) | -30.93 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 13, 2026 |
| Ask | 143.64 |
| Volume | 24,703 |
| Avg. Volume (20D) | 321,109 |
| Open | 109.23 |
| Previous Close | 112.86 |
| Day's Range | 107.22 - 111.16 |
| 52-Week Range | 26.19 - 155.29 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About INBX
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the trea...
Financial Performance
In 2025, Inhibrx Biosciences's revenue was 1.3M, an increase of 550% compared to the previous year's 200K. Earnings were -140.06M, a decrease of -108.3%.
Financial StatementsEarnings Surprise
- Revenue of $0 misses estimates by $0, with -100.00% YoY decline.
- EPS of -2.34 misses estimates by -0.06, with -26.49% YoY decline.
Analysts project revenue of ... Upgrade
4 months ago · Simply Wall St.
Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure BuildsMerck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data fo...
